TY - JOUR
T1 - Fertility among testicular cancer survivors
T2 - A case-control study in the U.S
AU - Kim, Christopher
AU - McGlynn, Katherine A.
AU - McCorkle, Ruth
AU - Zheng, Tongzhang
AU - Erickson, Ralph L.
AU - Niebuhr, David W.
AU - Ma, Shuangge
AU - Zhang, Yaqun
AU - Bai, Yana
AU - Dai, Li
AU - Graubard, Barry I.
AU - Kilfoy, Briseis
AU - Barry, Kathryn Hughes
AU - Zhang, Yawei
N1 - Funding Information:
The study was approved by Institutional Review Boards of Yale University, the National Cancer Institute, and the Walter Reed Army Institute for Research.
Funding Information:
Acknowledgments This study is supported by grant CA130110 from the National Cancer Institute (NCI) and by Fogarty training grants 1D43TW008323-01 and 1D43TW007864-01 from the National Institute of Health (NIH). This publication was made possible by CTSA Grant number UL1 RR024139 from the National Center for Research Resources (NCRR), a component of the NIH and NHL roadmap for medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR. The authors are greatly indebted to the Study participants, without whom, there would have been no study. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense.
PY - 2010
Y1 - 2010
N2 - Introduction: Testicular germ cell tumors (TGCT) disproportionately affect men between the ages of 15 and 49 years, when reproduction is typical. Although TGCT treatment directly affects gonadal tissues, it remains unclear whether there are long-term effects on fertility. Methods: To examine post-TGCT treatment fertility, study participants in a previously conducted case-control study were contacted. The men were initially enrolled in the US Servicemen's Testicular Tumor Environmental and Endocrine Determinants (STEED) study between 2002 and 2005. A total of 246 TGCT cases and 236 controls participated in the current study and completed a self-administered questionnaire in 2008-2009. Results: TGCT cases were significantly more likely than controls to experience fertility distress (OR 5.23; 95% CI 1.99-13.76) and difficulty in fathering children (OR 6.41; 2.72-15.13). Cases were also more likely to be tested for infertility (OR 3.65; 95% CI 1.55-8.59). Cases, however, did not differ from controls in actually fathering children (OR 1. 37;95% CI 0.88-2.15). These findings were predominantly observed among nonseminoma cases and cases treated with surgery only or surgery-plus-chemotherapy. Discussion: While expressing greater fertility distress, higher likelihood of fertility testing, and difficulty fathering children, these data suggest that TGCT survivors are no less likely to father children than are other men. It is possible that treatment for TGCT does not permanently affect fertility or, alternatively, that TGCT survivors attempt to father children with greater persistence or at younger ages than do other men.
AB - Introduction: Testicular germ cell tumors (TGCT) disproportionately affect men between the ages of 15 and 49 years, when reproduction is typical. Although TGCT treatment directly affects gonadal tissues, it remains unclear whether there are long-term effects on fertility. Methods: To examine post-TGCT treatment fertility, study participants in a previously conducted case-control study were contacted. The men were initially enrolled in the US Servicemen's Testicular Tumor Environmental and Endocrine Determinants (STEED) study between 2002 and 2005. A total of 246 TGCT cases and 236 controls participated in the current study and completed a self-administered questionnaire in 2008-2009. Results: TGCT cases were significantly more likely than controls to experience fertility distress (OR 5.23; 95% CI 1.99-13.76) and difficulty in fathering children (OR 6.41; 2.72-15.13). Cases were also more likely to be tested for infertility (OR 3.65; 95% CI 1.55-8.59). Cases, however, did not differ from controls in actually fathering children (OR 1. 37;95% CI 0.88-2.15). These findings were predominantly observed among nonseminoma cases and cases treated with surgery only or surgery-plus-chemotherapy. Discussion: While expressing greater fertility distress, higher likelihood of fertility testing, and difficulty fathering children, these data suggest that TGCT survivors are no less likely to father children than are other men. It is possible that treatment for TGCT does not permanently affect fertility or, alternatively, that TGCT survivors attempt to father children with greater persistence or at younger ages than do other men.
KW - Epidemiology
KW - Fertility
KW - Testicular cancer
UR - http://www.scopus.com/inward/record.url?scp=78649631577&partnerID=8YFLogxK
U2 - 10.1007/s11764-010-0134-x
DO - 10.1007/s11764-010-0134-x
M3 - Article
C2 - 20571931
AN - SCOPUS:78649631577
SN - 1932-2259
VL - 4
SP - 266
EP - 273
JO - Journal of Cancer Survivorship
JF - Journal of Cancer Survivorship
IS - 3
ER -